GLP-1 Receptor Agonists Explained

GLP-1 receptor agonists are a class of incretin-mimetic peptides that bind the glucagon-like peptide-1 receptor to drive insulin secretion, slow gastric emptying, and suppress appetite. The field has moved fast: five years ago, Semaglutide was the headline molecule; today, dual and triple receptor agonists like Tirzepatide and Retatrutide are reshaping metabolic research. Here is the landscape, in plain language.

The Three Receptors That Matter

• •GLP-1 (glucagon-like peptide-1), drives insulin secretion, slows gastric emptying, suppresses appetite via the hypothalamus.
• •GIP (glucose-dependent insulinotropic polypeptide), boosts insulin response and modulates fat metabolism.
• •Glucagon receptor, increases energy expenditure and lipolysis.

The newer multi-agonists target two or three of these receptors simultaneously, which is why their effects exceed what any single-receptor molecule can achieve.

Single Agonist: Semaglutide (GLP-1)

Semaglutide is a long-acting GLP-1 agonist with a 7-day half-life thanks to a fatty acid side chain that binds plasma albumin. It is the benchmark molecule in modern incretin research.

Dual Agonist: Tirzepatide (GLP-1 + GIP)

Tirzepatide hits both GLP-1 and GIP receptors. The dual signal produces stronger insulin response and noticeably greater body composition shifts in research models compared with GLP-1 alone.

Triple Agonist: Retatrutide (GLP-1 + GIP + Glucagon)

Retatrutide adds glucagon receptor activity to the dual mechanism. The glucagon arm increases energy expenditure, which is why early research data show the largest weight-loss magnitude of any peptide in this class.

Other Notable Molecules

• •Mazdutide, GLP-1 + glucagon dual agonist, China-led research.
• •Survodutide, GLP-1 + glucagon, studied in liver and metabolic research.
• •CagriSema, Semaglutide + Cagrilintide (amylin analog) combination.

Where Research Is Heading

• •Tissue-specific signaling, selective GLP-1 agonists that engage central but not peripheral receptors.
• •Oral formulations with bioavailability problems finally solved.
• •Muscle-sparing combinations that pair incretins with myostatin inhibitors.

For researchers, the takeaway is simple: incretins are no longer one molecule, they are a platform that is rapidly diversifying.

A Brief History, Why This Class Exists

The GLP-1 story begins with a pancreatic enzyme observation in the 1980s and the realization that a hormone released from the gut after eating amplified insulin secretion far more than glucose alone could account for. That hormone, glucagon-like peptide-1, was identified as the dominant incretin. The native molecule has a half-life of about two minutes, degraded almost immediately by DPP-4. Forty years of medicinal chemistry to make GLP-1 stable and long-acting produced the molecules now reshaping metabolic medicine.

The Three Receptors Explained in More Detail

GLP-1

• •Released from intestinal L-cells in proportion to nutrient load
• •Glucose-dependent insulin secretion (no insulin without glucose, hence low hypoglycemia risk)
• •Suppresses glucagon
• •Slows gastric emptying, dominant mechanism behind early fullness
• •Acts on the hypothalamus and reward circuits, reduced appetite and "food noise"
• •Has direct cardiovascular effects independent of weight loss

GIP

• •Released from intestinal K-cells
• •Amplifies glucose-dependent insulin secretion (synergistic with GLP-1)
• •Modulates fat metabolism, affects how energy is stored and mobilized
• •Has more complex appetite effects than originally thought; the dual GIP/GLP-1 effect produces stronger satiety than GLP-1 alone

Glucagon Receptor

• •Increases hepatic glucose output (a feature, not a bug, when balanced)
• •Increases energy expenditure, the metabolic rate goes up
• •Drives lipolysis, fat is mobilized for energy
• •Adding glucagon agonism to GLP-1/GIP is what gives the triple agonists their additional weight-loss magnitude

Why Receptor Selectivity and Pharmacokinetics Matter

The reason different molecules in this class produce different outcomes is not just *which receptors* they hit but *with what affinity, in what ratio, and over what timescale*. Tirzepatide, for instance, has higher affinity at GIP than at GLP-1, with a roughly 5-day half-life. Retatrutide rebalances the ratios across all three receptors. Mazdutide hits GLP-1 + glucagon. The variations are deliberate and produce distinct efficacy and tolerability profiles.

The Trial Data, Briefly

• •Semaglutide 2.4 mg (STEP-1): −14.9% body weight at 68 weeks (NEJM, 2021)(1)
• •Tirzepatide 15 mg (SURMOUNT-1): −20.9% body weight at 72 weeks (NEJM, 2022)(2)
• •Retatrutide 12 mg (Phase II): −24.2% body weight at 48 weeks (NEJM, 2023)(3)
• •Semaglutide for cardiovascular outcomes (SELECT): −20% MACE in non-diabetic obesity with prior CVD (NEJM, 2023)(4)
• •Tirzepatide for sleep apnea (SURMOUNT-OSA): ~30 events/hour reduction in AHI (2024)

These are the headline trials. The full evidence base across STEP, SURMOUNT, SUSTAIN, SURPASS, REWIND, LEADER, and adjacent programs is now one of the largest in modern pharmacology.

Other Notable Molecules in the Class

• •Mazdutide, GLP-1 + glucagon dual agonist, China-led development, strong weight and metabolic data
• •Survodutide, GLP-1 + glucagon, also being investigated for liver disease (MASH/NASH)
• •CagriSema, Semaglutide + Cagrilintide (an amylin analog) combination, with promising additive weight effects
• •Orforglipron, small molecule oral GLP-1 agonist (not a peptide, but worth noting); could disrupt the injectable model
• •Mounjaro vs Zepbound, same molecule (tirzepatide), different brand for different indications

Tolerability, What Trials and Practice Show

GI side effects are dose-dependent and dominate the tolerability picture:

• •Nausea, vomiting, diarrhea, 30–50% of subjects, usually transient with slow titration
• •Constipation, common, often persistent
• •Gallbladder events, small but consistent signal
• •Pancreatitis, no causal link in pooled analyses
• •Lean mass loss, without resistance training and adequate protein, 25–40% of weight lost is lean mass

The lean mass issue is the single most important behavioral overlay on any GLP-1 protocol.

Where Research Is Heading

• •Tissue-specific signaling, selective GLP-1 agonists that engage central but not peripheral receptors, reducing GI side effects
• •Oral formulations with absorption-enhancer technology finally producing meaningful bioavailability
• •Muscle-sparing combinations, pairing incretins with myostatin inhibitors or activin receptor modulators
• •Novel indications, Alzheimer's, Parkinson's, MASH/NASH, addictive disorders, polycystic ovary syndrome, all under active investigation
• •Pediatric and adolescent expansion, STEP TEENS already positive, regulatory pathway opening

How Research Protocols Are Structured

Published clinical trial designs in this class share a recurring pattern: gradual dose titration over an 8-12 week period, standardized protein-intake and resistance-training study variables, defined baseline and follow-up laboratory panels, and a planned maintenance-phase study arm rather than abrupt discontinuation, reflecting the trial finding that discontinuation is associated with substantial regain.

Summary

Incretin pharmacology is no longer one molecule. It is a platform that is rapidly diversifying across receptors, tissues, and indications. The class has produced the largest weight-loss and cardiometabolic effect sizes in modern pharmacology. The under-discussed risks, lean mass loss, abrupt-withdrawal regain, GI tolerability, are manageable with structured protocols. For research purposes, the field is in one of its most active phases in decades.

Frequently Asked Questions

What does GLP-1 do endogenously?

GLP-1 is an incretin released from intestinal L-cells after eating. It amplifies glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite.

Which agents are in the class?

Semaglutide, liraglutide, dulaglutide, exenatide (pure GLP-1); tirzepatide (GIP/GLP-1 dual); retatrutide (GIP/GLP-1/glucagon triple, investigational).

Why do side effects peak early?

Gastric-emptying slowdown adapts over 8–12 weeks. Escalation schedules are designed to give receptors time to desensitize.

Do the effects reverse if the peptide is stopped?

Yes. Extension trials show substantial weight regain within 12 months of discontinuation.

Is GLP-1 activity limited to weight and glucose?

No. Receptors are expressed in the heart, kidneys, and CNS, which explains the cardiovascular, renal, and possibly neurodegenerative signals emerging across trials.

References

1. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. PMID: 33567185.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. PMID: 35658024.
3. Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. PMID: 37366315.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity. N Engl J Med. 2023 Dec 14. PMID: 37952131.